Mutational and Epigenetic Evidence for Independent Pathways for Lung Adenocarcinomas Arising in Smokers and Never Smokers
Open Access
- 1 February 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (3) , 1371-1375
- https://doi.org/10.1158/0008-5472.can-05-2625
Abstract
Genetic and epigenetic alterations are considered to play important roles in lung cancer. Recent studies showed that EGFR and K-RAS mutations exhibited a mutually exclusive pattern in adenocarcinoma of the lung, suggesting the presence of two independent oncogenic pathways. However, it is unknown how epigenetic alterations were involved in lung carcinogenesis mediated by EGFR or K-RAS mutation. In this study, we examined the relationship between genetic and epigenetic alterations in 164 cases of lung adenocarcinoma. Somatic mutations were determined by direct sequence of EGFR exons 18 to 21 and K-RAS codons 12 and 13. Methylation status of p16INK4a, RASSF1A, APC, RARβ, and CDH13, frequently methylated in lung cancer, was determined by methylation-specific PCR and the degree of methylation was defined as the methylation index. Multivariate analysis adjusted for age, sex, and smoking dose showed that the probability of having EGFR mutation was significantly lower among those with p16INK4a and CDH13 methylation than in those without [p16INK4a: odds ratio (OR), 0.07; 95% confidence interval (95% CI), 0.02-0.33; CDH13: OR, 0.34; 95% CI, 0.15-0.77] and the methylation index was significantly lower in EGFR mutant cases than in wild type (OR, 0.70; 95% CI, 0.52-0.95). By contrast, K-RAS mutation was significantly higher in p16INK4a methylated cases than in unmethylated cases (OR, 4.93; 95% CI, 1.54-15.7) and the methylation index was higher in K-RAS mutant cases than in wild type with marginal significance (OR, 1.46; 95% CI, 0.95-2.25). Our results indicate the differences in the evolvement of epigenetic alterations between the EGFR- and K-RAS-mediated tumorigenesis and suggest the specific interaction of genetic and epigenetic changes in tumorigenesis of lung cancer. (Cancer Res 2006; 66(3): 1371-5)Keywords
This publication has 19 references indexed in Scilit:
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung CancersJNCI Journal of the National Cancer Institute, 2005
- Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokersInternational Journal of Cancer, 2004
- Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA MethylationJournal of Clinical Oncology, 2004
- Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?Trends in Molecular Medicine, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- RASSF1A gene inactivation in non‐small cell lung cancer and its clinical implicationInternational Journal of Cancer, 2003
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Molecular Pathogenesis of Lung CancerAnnual Review of Physiology, 2002
- Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4aCell, 1997